XML 35 R23.htm IDEA: XBRL DOCUMENT v3.20.2
Segment Information
 6 Months Ended
Jun. 30, 2020
Segment Reporting [Abstract]  
Segment Information Segment Information
Information regarding the Company’s segments for the three and six months ended June 30, 2020 and 2019 is as follows:
Revenues by segmentThree Months EndedSix Months Ended
June 30,June 30,
(in thousands)2020201920202019
Medical Devices$5,148  $7,422  $11,133  $14,148  
Strategic Positions—  —  —  —  
Pharmaceutical—  —  —  —  
Income Generating Assets63  36  73  6  
Total revenues$5,211  $7,458  $11,206  $14,154  
________________
The table above excludes revenues related to discontinued operations. See Note 2, Discontinued Operations Classified as Assets Held for Sale, for additional information.
(Loss) income by segmentThree Months EndedSix Months Ended
June 30,June 30,
(in thousands)2020201920202019
Medical Devices$(2,559) $(1,678) $(4,670) $(2,893) 
Strategic Positions (1)
(4,823) 19,044  (15,723) 19,044  
Pharmaceutical (1)
(14,475) (345) (16,542) 5,300  
Income Generating Assets (1)
(22,773) (21,440) (39,418) (19,190) 
Total(44,630) (4,419) (76,353) 2,261  
Change in fair value of warrants not allocated to segments (2)
(5,341) —  (5,341) —  
Net (loss) income attributable to PDL’s shareholders$(49,971) $(4,419) $(81,694) $2,261  
________________
(1) The (Loss) income by segment presented above includes amounts related to both continuing and discontinued operations. See Note 2, Discontinued Operations Classified as Assets Held for Sale, for additional information.
(2) The change in fair value of warrants not allocated to segments presented above includes the amounts related to the change in fair value of the Evofem warrants after the distribution of the Evofem common stock to PDL stockholders on May 21, 2020. The Strategic Positions segment ceased to be a reporting segment as of this date.

Information regarding the Company’s segments as of June 30, 2020 and December 31, 2019 is as follows:
Long-lived assets by segment
(in thousands)June 30,
2020		December 31,
2019
Medical Devices$2,974  $2,435  
Strategic Positions—  —  
Pharmaceutical (1)
2,949  2,960  
Income Generating Assets64  125  
Total long-lived assets (1)
$5,987  $5,520  
________________
(1) The amounts above include Property and Equipment in the Pharmaceutical segment classified as Assets held for sale. See Note 2, Discontinued Operations Classified as Assets Held for Sale, for additional information.

The operations for the Medical Devices segment are primarily located in the United States and the operations for the Pharmaceutical segment are primarily located in Italy, Ireland and the United States.